Upregulation of deubiquitinase USP7 by transcription factor FOXO6 promotes EC progression via targeting the JMJD3/CLU axis

• Published in: Molecular therapy. Oncolytics 2021-03, Vol.20, p.583-595
• Main Authors: Li, Nuo, Zhao, Zhifeng, Liu, Pengliang, Zheng, Yan, Cai, Shuang, Sun, Yin, Wang, Baoming
• Format: Article
• Language: English
• Subjects: CLU; esophageal carcinoma; FOXO6; H3K27me3; JMJD3; Original; ubiquitination; USP7
• ISSN: 2372-7705; 2372-7705
• DOI: 10.1016/j.omto.2020.12.008

Esophageal carcinoma (EC) is recognized as one of the most frequently occurring malignancies worldwide, and its high morbidity rate motivates efforts to identify potential therapeutic targets. Notably, forkhead box (FOX) family genes are highlighted as possible biomarkers for diagnostics, prognostics, and therapeutics of various malignancies, including EC. Our present study was performed to investigate the underlying mechanism of FOXO6 on the development of EC. We observed a significant upregulation of FOXO6 in EC tissues, contributing to the migration and proliferation in EC cells through gain- and loss-of-function assays. FOXO6 directly interacted with the ubiquitin-specific processing protease 7 (USP7) gene promoter and enhanced its transcriptional activity, which resulted in suppressed cancer cell apoptosis as revealed by chromatin immunoprecipitation (ChIP)-qPCR. USP7 enhanced the ubiquitination of Jumonji domain-containing protein D3 (JMJD3), elevated JMJD3-promoted growth of EC cells, and transcriptionally activated clusterin (CLU) expression at the promoter region via histone H3 lysine 27 tri-methyl (H3K27me3) demethylation, according to immunoprecipitation and ubiquitination assays. Finally, we verified that FOXO6 mediated effects on the USP7/JMJD3/CLU axis to exert an oncogenic role in vivo, which was blocked by USP7 and JMJD3 inhibitor. Our findings demonstrate an important role of the FOXO6/USP7/JMJD3/CLU pathway in EC progression and thus provide attractive potential therapeutic targets for EC patients. [Display omitted] This study aimed at researching the function of FOXO6 on EC. FOXO6 overexpression or JMJD3 overexpression was observed to promote the development of EC. FOXO6 promoted USP7 expression, which enhanced JMJD3 ubiquitination and promoted CLU expression. This study highlights that the FOXO6/USP7/JMJD3/CLU axis may be a novel therapeutic target for EC.